Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02191215

Enrollment

442

Registered

2014-07-16

Start date

2003-06-30

Completion date

Unknown

Last updated

2014-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immunodeficiency Syndrome

Brief summary

The aim of the Post Marketing Study (PMS) is to evaluate the efficacy and safety profile of nevirapine in the management of the HIV/AIDS in an open environment.

Interventions

DRUGNevirapine (Viramune®)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* diagnosis of HIV/AIDS, no age limits * patients could be naïve to treatment or pretreated with other antiretroviral agents

Exclusion criteria

* Patients with known hypersensitivity to nevirapine or any other component of the product

Design outcomes

Primary

Measure	Time frame
Number of patients with adverse event	up to 90 days
Change in body weight	Baseline, up to 90 days
Change in cluster of differentiation 4 (CD4) cell count	Baseline, up to 90 days
Change in viral load (HIV RNA)	Baseline, up to 90 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026